Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Anna Ng

Physician Assistant Woodbury, NJ Physician Assistant

NPI 1508047127 CMS profile 11102112

17 W Red Bank Ave Ste 205, Woodbury, NJ 08096

Open in the dashboard

General payments

$11,254

572 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Anna Ng of Woodbury, NJ is reported in the CMS Open Payments database as having received $11,254 across 572 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,631 127
2024 General $2,672 144
2023 General $2,050 100
2022 General $1,914 107
2021 General $1,987 94

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Anna Ng
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Anna Ng were reported at $2,631. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Anna Ng Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $1,987 $132 $37–$438 $132
2022 $1,914 $155 $48–$522 $149
2023 $2,050 $167 $52–$557 $160
2024 $2,672 $178 $55–$600 $164
2025 $2,631 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $2,012 123 payments
  2. Janssen Biotech, Inc. $1,203 43 payments
  3. Lilly USA, LLC $992 53 payments
  4. Sun Pharmaceutical Industries Inc. $921 41 payments
  5. UCB, Inc. $800 30 payments
  6. Ortho Dermatologics, a division of Bausch Health US, LLC $735 29 payments
  7. Incyte Corporation $703 36 payments
  8. Novartis Pharmaceuticals Corporation $554 39 payments
  9. Regeneron Healthcare Solutions, Inc. $549 22 payments
  10. LEO Pharma Inc. $485 33 payments
  11. Other $2,300 123 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $10,675 565 payments
  2. Education $579 7 payments
Products named General payments · program years 2021–2025
  1. SKYRIZI $1,148 61 payments
  2. TREMFYA $1,108 34 payments
  3. TALTZ $723 48 payments
  4. OPZELURA $703 36 payments
  5. RINVOQ $687 53 payments
  6. Bimzelx $609 17 payments
  7. CIBINQO $446 26 payments
  8. Winlevi $439 20 payments
  9. SOTYKTU $389 25 payments
  10. ADBRY $386 26 payments
  11. Other $6,309 362 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

186

Median for Physician Assistant: 241

Drug cost

$48,496

Median for Physician Assistant: $4,110

Branded share of claims

14%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Pen Dupilumab Brand 11 $43,627
Fluorouracil Generic 27 $1,845
Clobetasol Propionate Generic 55 $1,738
Mometasone Furoate Generic 28 $442
Triamcinolone Acetonide Generic 15 $313
Ciclopirox Ciclopirox Olamine Brand 15 $232
Ketoconazole Generic 11 $172
Doxycycline Hyclate Generic 11 $75
Minoxidil Generic 13 $55

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 26 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Zoryve
  • Arcutis Biotherapeutics, Inc. $267
$267 — —
OPZELURA
  • Incyte Corporation $243
$243 — —
TREMFYA
  • Janssen Biotech, Inc. $238
$238 — —
COSENTYX
  • Novartis Pharmaceuticals Corporation $189
$189 — —
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $160
  • GENZYME CORPORATION $16
$175 11 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 26 with Patron

Records

572 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record